Check Before You Invest : Sandu Pharmaceuticals Ltd

Q: Which industry/sub-sector does Sandu Pharmaceuticals Ltd belong to?

Sandu Pharmaceuticals Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q: Is Sandu Pharmaceuticals Ltd a good quality company?

Sandu Pharmaceuticals Ltd is a quality company, based on a multi-year financial track record. This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

Q: Is Sandu Pharmaceuticals Ltd undervalued or overvalued?

Sandu Pharmaceuticals Ltd appears Fair, as its key valuation ratios are in line with their past averages. Based on the industry it operates in, the relevant valuation ratios include one of the following, P/E, P/BV, P/Sales, EV/EBITDA or a combination of two or more. Valuation Ratios. Price to Earnings, Current: 21.53, Historic Median: 35.79. Price to Book, Current: 1.08, Historic Median: 1.80. Price to Sales, Current: 0.54, Historic Median: 0.83. EV to EBITDA, Current: 9.04, Historic Median: 16.80

Q: Is Sandu Pharmaceuticals Ltd a good buy now?

Sandu Pharmaceuticals Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Q: Revenue growth of Sandu Pharmaceuticals Ltd?

Sandu Pharmaceuticals Ltd revenue growth is -0.1% for FY-2025, which is below its 5-year CAGR of 6.76%, indicating slower growth.

Q: Gross Profit margin of Sandu Pharmaceuticals Ltd?

Sandu Pharmaceuticals Ltd Gross profit margin which is the profit after deduction of direct costs, is 4.2% for FY-2025, which is in line with its 5-year median of 4.2%, indicating stable margins.

Q: Operating Profit Margin of Sandu Pharmaceuticals Ltd?

Sandu Pharmaceuticals Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 4.11% for FY-2025, which is above its 5-year median of 3.81% indicating increasing margins.

Q: Net Profit Margin of Sandu Pharmaceuticals Ltd?

Sandu Pharmaceuticals Ltd Net Profit Margin is 2.31% for FY-2025, is in line with its 5-year median of 2.31%, indicating stable margins. Profitability Metrics. Gross Profit Margin (%), Current: 4.2, Historic Median: 4.2. Operating Profit Margin (%), Current: 4.11, Historic Median: 3.81. Net Profit Margin (%), Current: 2.31, Historic Median: 2.31

Q: Return on Asset of Sandu Pharmaceuticals Ltd?

Sandu Pharmaceuticals Ltd Return on Asset is 2.86%, which is in line with its 5-year historical median of 2.86%, indicating stable asset utilization efficiency.

Q: Return on capital employed (ROCE) of Sandu Pharmaceuticals Ltd?

Sandu Pharmaceuticals Ltd Return on capital employed is 6.91% for FY-2025, which is in line with its 5-year historical median of 6.91%. The current ROCE is below its estimated weighted average cost of capital (WACC) of 14%, indicating value preservation.

Check Before You Invest : Sandu Pharmaceuticals Ltd

Snapshot

Q.1 Which industry/sub-sector does Sandu Pharmaceuticals Ltd belong to?

Sandu Pharmaceuticals Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.2 Is Sandu Pharmaceuticals Ltd a good quality company?

Sandu Pharmaceuticals Ltd is a quality company, based on a multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

Q.3 Is Sandu Pharmaceuticals Ltd undervalued or overvalued?

Sandu Pharmaceuticals Ltd appears Fair, as its key valuation ratios are in line with their past averages.

Based on the industry it operates in, the relevant valuation ratios include one of the following, P/E, P/BV, P/Sales, EV/EBITDA or a combination of two or more.

Valuation Ratios	Current	5-year Historic Median
Price to Earnings	21.53	35.79
Price to Book	1.08	1.80
Price to Sales	0.54	0.83
EV to EBITDA	9.04	16.80

Q.4 Is Sandu Pharmaceuticals Ltd a good buy now?

Sandu Pharmaceuticals Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

A: What are the trends in revenue and profit margins?

Q.1 Revenue growth of Sandu Pharmaceuticals Ltd?

Sandu Pharmaceuticals Ltd revenue growth is -0.1% for FY-2025, which is below its 5-year CAGR of 6.76%, indicating slower growth.

Q.2 Gross Profit margin of Sandu Pharmaceuticals Ltd?

Sandu Pharmaceuticals Ltd Gross profit margin which is the profit after deduction of direct costs, is 4.2% for FY-2025, which is in line with its 5-year median of 4.2%, indicating stable margins.

Q.3 Operating Profit Margin of Sandu Pharmaceuticals Ltd?

Sandu Pharmaceuticals Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 4.11% for FY-2025, which is above its 5-year median of 3.81% indicating increasing margins.

Q.4 Net Profit Margin of Sandu Pharmaceuticals Ltd?

Sandu Pharmaceuticals Ltd Net Profit Margin is 2.31% for FY-2025, is in line with its 5-year median of 2.31%, indicating stable margins.

	Current Level	5-year Historic Median
Gross Profit Margin (%)	4.2	4.2
Operating Profit Margin (%)	4.11	3.81
Net Profit Margin (%)	2.31	2.31

B: Does the business utilize capital efficiently?

Q.5 Return on Asset of Sandu Pharmaceuticals Ltd?

Sandu Pharmaceuticals Ltd Return on Asset is 2.86%, which is in line with its 5-year historical median of 2.86%, indicating stable asset utilization efficiency.

Q.6 Return on capital employed (ROCE) of Sandu Pharmaceuticals Ltd?

Sandu Pharmaceuticals Ltd Return on capital employed is 6.91% for FY-2025, which is in line with its 5-year historical median of 6.91%. The current ROCE is below its estimated weighted average cost of capital (WACC) of 14%, indicating value preservation.

Q.7 Return on Equity (ROE) of Sandu Pharmaceuticals Ltd?

Sandu Pharmaceuticals Ltd Return on equity is 4.74% for FY-2025, which is in line with its 5-year historical median of 4.74%, indicating the business is making similar use of its shareholders capital.

Q.8 Cash conversion cycle of Sandu Pharmaceuticals Ltd?

Sandu Pharmaceuticals Ltd Cash conversion cycle is 72 days, above its 5-year historical median of 50 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.

	Current Level	5-year Historic Median
Asset Turnover (x)	1.24	1.26
ROE (%)	4.74	4.74
ROCE (%)	6.91	6.91
Cash Conversion Cycle	72 days	50 days

C: How much debt does the business have and is it at a sustainable level?

Q.9 Debt to Equity ratio of Sandu Pharmaceuticals Ltd?

Sandu Pharmaceuticals Ltd Debt-to-Equity ratio is 0.00, which is lower the industry average of 0.14, indicating lower debt levels in the industry.

Q.10 Debt to cash flow from operations of Sandu Pharmaceuticals Ltd?

Sandu Pharmaceuticals Ltd Debt to cash flow from operations is 0, which is at a healthy level.

Ownership & governance

D: Promoter shareholding and pledge status of Sandu Pharmaceuticals Ltd?

Q.1 Promoter shareholding and pledge status of Sandu Pharmaceuticals Ltd?

Promoters hold 37.79% of the Sandu Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

E: How does Sandu Pharmaceuticals Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Sandu Pharmaceuticals Ltd vs industry peers?

Sandu Pharmaceuticals Ltd revenue CAGR is 6.76%, compared to the industry median CAGR of 5.35%, indicating faster growth and gaining its market share.

Profit Metrics

	Current Level	5-year Industry Median
Revenue Growth (%)	-0.1	5.4
Gross Profit Growth (%)	6.4	14
Operating Profit Growth (%)	20	11.5
Net Profit Growth (%)	6.2	12

Operating Efficiency

	Current Level	5-year Industry Median
Asset Turnover (x)	1.24	0.79
ROE (%)	4.74	9.17
ROCE (%)	6.91	11.52
Cash Conversion Cycle (days)	71.6	76

Valuation & price assessment

Q.1 Stock return of Sandu Pharmaceuticals Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 3.1% based on the current price.

	9Y	5Y	3Y	1Y
Share Price CAGR	3.1%	-0.5%	-11.7%	-29.7%

Q.2 Valuation ratios of Sandu Pharmaceuticals Ltd vs historical?

The current P/E ratio of 21.53 is lower than its historical median of 35.79, indicating that the stock is trading below its historical average valuation.

Q.3 How do the current valuation ratios compare with 5-year historical median and industry numbers?

Valuation Ratios	Current	5-year Historic Median	5-year Industry Median
Price to Earnings	21.53	35.79	31.09
Price to Book	1.08	1.80	2.85
Price to Sales	0.54	0.83	2.82
EV to EBITDA	9.04	16.80	15.99

Check more companies

3. Wockhardt

8. Neuland Laboratories

9. Astrazeneca Pharma I

10. Onesource Specialty

Check trending companies

1. The Great Eastern Shipping Company Ltd.

2. PB Fintech Ltd.

3. Go Digit General Insurance Ltd.

4. Gillette India Ltd.

5. Tata Communications Ltd.

Check Before You Invest : Sandu Pharmaceuticals Ltd

Snapshot

Performance Analysis

Ownership & governance

Peer comparison (industry-wise, mcap)

Profit Metrics

Operating Efficiency

Valuation & price assessment

Check more companies

Check trending companies

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.